Variantyx

We See More In Every Genetic Test

Boston, United States · Founded 2014 · $100.0M raised

Employees
51–200
Founded
2014
Business Model
B2B
Total Funding
$100.0M
Last Round
$36.0M Series DApr 2024
Rounds
6

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 7 funding rounds and 7 investors for this company. The full record is or through the API.

About

Variantyx is a molecular diagnostics company offering whole-genome-based genetic testing for rare genetic disorders, neurology, reproductive genetics, and precision oncology. Its Genomic Unity platform delivers comprehensive variant detection using both short-read and Oxford Nanopore long-read whole genome sequencing, serving clinicians and healthcare providers.

Summary

Variantyx is a Diagnostics company based in Boston, United States, founded in 2014. It has raised $100.0M in total across 6 rounds, most recently a $36.0M Series D round in Apr 2024. Investors include Kreos Capital, GHS Fund and New Era Capital Partners.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series DSeries DApr 2024
$36.0M

Sign up to see all 7 events

Funding: Seed through Series D. Amounts, valuations, and investors where available.

Investors

Similar Companies

Caris Life SciencesIPO

Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...

Irving, United States1001–5000Diagnostics, Genomics
Growth EquityTotal funding$1.5BApr 2025
Foundation MedicineAcquired

Provides genomic profiling tests and data services to oncologists and biopharma partners to guide...

Cambridge, United States1001–5000Diagnostics, Genomics
Corporate RoundTotal funding$1.1BJan 2015
Helix

Population genomics and viral surveillance company enabling health systems and public health orga...

San Mateo, United States201–500Biotech, Diagnostics
Series CTotal funding$435.0MJun 2021
BillionToOneIPO

BillionToOne develops single-molecule diagnostic tests that improve prenatal screening and help c...

Menlo Park, United States201–500Biotech, Diagnostics
Venture RoundTotal funding$406.0MMar 2026
NateraIPO

Natera develops cell-free DNA tests that help clinicians guide care in oncology, women’s health, ...

San Carlos, United States5001–10000Diagnostics, Genomics
Series ETotal funding$310.1MJul 2019
Personal Genome DiagnosticsAcquired

Innovative genomic technologies to solve fundamental challenges in oncology

Baltimore, United States51–200Biotech, Diagnostics
Series CTotal funding$244.5MFeb 2021

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Variantyx on Indexed.vc
<a href="https://indexed.vc/companies/variantyx"><img src="https://indexed.vc/api/badge/company/variantyx" alt="Variantyx on Indexed.vc" width="260" height="76" /></a>